Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Khromova

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Optics Express|May 4, 2016
Tunable beam steering enabled by graphene metamaterialsB Orazbayev, M Beruete, I Khromova
Neuroreport|May 30, 1995
Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of MeynertI Khromova, P Rauhala, N Zolotov, et al.
Behavioural Brain Research|June 1, 1997
Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male ratsI Khromova, T Voronina, V A Kraineva, et al.
HIV Medicine|October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensA Cozzi-Lepri, R Zangerle, L Machala, et al.
HIV Medicine|February 2, 2018
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in EuropeJ R Santos, A Cozzi-Lepri, A Phillips, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Optics Express|May 4, 2016
Tunable beam steering enabled by graphene metamaterialsB Orazbayev, M Beruete, I Khromova
Neuroreport|May 30, 1995
Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of MeynertI Khromova, P Rauhala, N Zolotov, et al.
Behavioural Brain Research|June 1, 1997
Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male ratsI Khromova, T Voronina, V A Kraineva, et al.
HIV Medicine|October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensA Cozzi-Lepri, R Zangerle, L Machala, et al.
HIV Medicine|February 2, 2018
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in EuropeJ R Santos, A Cozzi-Lepri, A Phillips, et al.
Pageof 1